Single digit gradients

Protect your patient's future. Minimise the risk of patient-prosthesis mismatch, even in patient with small annuli.

Heart Icon

1.7 cm2


Heart Beat

8.0 mmHg


Drop Icon

2.7 %

Severe prosthesis-patient mismatch – compared to 15% (P< 0,001) for SAPIEN 3 Ultra3

See ACURATE neo2 in action

The self-expanding, supra-annular valve structure reduces the risk of structural valve deterioration. ACURATE neo2™ has demonstrated large EOAs and low mean gradients up to 5 years.1 Large EOAs provide improved flow, less resistance, and better long-term durability.2

“From a surgical point of view we use supra-annular [valves] due to greater orifice area, minimizing the risk of PPM – it’s better for the patient.”

- Prof. Michael Zembala

ACURATE neo2 vs. SAPIEN 3 Ultra

First real-world analysis of device success and clinical safety in next-gen TAVI devices: the comparison of supra-annular ACURATE neo2 and intra-annular SAPIEN 3 Ultra valves.1

Elevated gradients*¹

2.6% ACURATE neo2 vs 9.8% SAPIEN 3 Ultra Valve

Severe prosthesis-patient mismatch¹

2.3% ACURATE neo2 vs. 15.5% SAPIEN 3 Ultra Valve

1. Pellegrini C. ACURATE neo2 versus SAPIEN 3 Ultra. EuroIntervention 2022. 
2. Flameng W, et al. Prosthesis-patient mismatch predicts structural valve degeneration in bioprosthetic heart valves. Circulation. 2010 May 3;121:2123-2129.

CAUTION: The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings and instructions for use can be found in the product labelling supplied with each device. Products shown for INFORMATION purposes only and may not be approved or for sale in certain countries. This material not intended for use in France. Product available in the European Economic Area (EEA) only. Please check availability with your local sales representative or customer service